From Fetal Growth Restriction to Adolescent Cardiometabolic Risk: The Impact of Catch-Up Growth and Adiposity

Anca Adam-Raileanu1, Alin Horatiu Nedelcu1, Mitica Ciorpac1

  • 1Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.

Nutrients
|March 14, 2026
PubMed

Insights

Postnatal growth acceleration, not just fetal size, increases cardiometabolic risk in adolescents born with fetal growth restriction (FGR). This catch-up growth impacts BMI, blood pressure, and adipokine signaling, highlighting key pathways for intervention.

Area of Science:

  • Endocrinology
  • Pediatric Cardiology
  • Developmental Biology

Background:

  • Fetal growth restriction (FGR) is linked to later-life cardiometabolic disorders.
  • Understanding the impact of intrauterine programming on adolescent health is crucial.

Purpose of the Study:

  • To investigate the relationship between birth weight, postnatal catch-up growth, adipokine signaling, and early cardiometabolic risk in adolescents.
  • To identify the mechanisms linking FGR to adolescent cardiometabolic outcomes.

Main Methods:

  • Cross-sectional study of 80 adolescents (40 FGR, 40 controls) matched for age and sex.
  • Assessment of anthropometry, blood pressure, lipid profile, glucose, and adipokines (leptin, adiponectin, ghrelin).
  • Analysis of associations between birth weight, growth rate, adipokines, and cardiometabolic markers.

Main Results:

  • Birth weight was not associated with cardiometabolic risk factors.
  • Catch-up growth in FGR adolescents correlated with increased BMI, central adiposity, and blood pressure.
  • BMI mediated the link between catch-up growth and cardiometabolic risk; this effect was amplified in overweight/obese adolescents.
  • Catch-up growth was linked to higher leptin levels and leptin/ghrelin ratio.

Conclusions:

  • Postnatal growth acceleration, not fetal size, is the primary driver of early cardiometabolic risk after FGR.
  • Adiposity-mediated and endocrine pathways, involving adipokines, are key mechanisms.
  • Targeting postnatal growth and adiposity may mitigate long-term cardiometabolic consequences of FGR.

Related Concept Videos

Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.8K
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.6K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312